Habi O.,Unite de Recherche en Pediatrie |
Girard J.,Unite de Recherche en Pediatrie |
Bourdages V.,Unite de Recherche en Pediatrie |
Delisle M.-C.,Unite de Recherche en Pediatrie |
Carreau M.,Unite de Recherche en Pediatrie
Anemia | Year: 2010
The main cause of morbidity and mortality in Fanconi anemia patients is the development of bone marrow (BM) failure; thus correction of hematopoietic stem cells (HSCs) through gene transfer approaches would benefit FA patients. However, gene therapy trials for FA patients using ex vivo transduction protocols have failed to provide long-term correction. In addition, ex vivo cultures have been found to be hazardous for FA cells. To circumvent negative effects of ex vivo culture in FA stem cells, we tested the corrective ability of direct injection of recombinant lentiviral particles encoding FancC-EGFP into femurs of Fanc C -/- mice. Using this approach, we show that Fanc C -/- HSCs were efficiently corrected. Intrafemoral gene transfer of the FancC gene prevented the mitomycin C-induced BM failure. Moreover, we show that intrafemoral gene delivery into aplastic marrow restored the bone marrow cellularity and corrected the remaining HSCs. These results provide evidence that targeting FA-deficient HSCs directly in their environment enables efficient and long-term correction of BM defects in FA.Copyright © 2010 Ouassila Habi et al.